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Abstract
 
Initiation of T cell antigen receptor (TCR) signaling is dependent on Lck, a Src family kinase.
The Src-like adaptor protein (SLAP) contains Src homology (SH)3 and SH2 domains, which
are highly homologous to those of Lck and other Src family members. Because of the structural
similarity between Lck and SLAP, we studied its potential role in TCR signaling. Here, we
show that SLAP is expressed in T cells, and that when expressed in Jurkat T cells it can specifi-
cally inhibit TCR signaling leading to nuclear factor of activated T cells (NFAT)-, activator
protein 1 (AP-1)–, and interleukin 2–dependent transcription. The SH3 and SH2 domains of
SLAP are required for maximal attenuation of TCR signaling. This inhibitory activity can be
bypassed by the combination of phorbol myristate acetate (PMA) and ionomycin, suggesting
that SLAP acts proximally in the TCR signaling pathway. SLAP colocalizes with endosomes in
Jurkat and in HeLa cells, and is insoluble in mild detergents. In stimulated Jurkat cells, SLAP as-
 
sociates with a molecular signaling complex containing CD3
 
z
 
, ZAP-70, SH2 domain–contain-
ing leukocyte protein of 76 kD (SLP-76), Vav, and possibly linker for activation of T cells
(LAT). These results suggest that SLAP is a negative regulator of TCR signaling.
Key words: Lck • Src homology 2 • T cell activation • calcium flux • endosomes
 
Introduction
 
Activation of the TCR is a critical event for T cell devel-
opment in the thymus, as well as for initiating immune re-
sponses in mature T cells. The TCR is devoid of intrinsic
catalytic activity, yet its engagement leads to significant in-
duction of protein tyrosine kinase activity, resulting in
phosphorylation of tyrosine residues on many proteins. Src
family protein tyrosine kinases, especially in T cells of one
of its members, Lck, have been shown to be responsible for
initiating this process by phosphorylating tyrosines within
 
immunoreceptor tyrosine-based activation motifs (ITAMs)
 
1
 
present within CD3 and 
 
z
 
 chains of the TCR (1). Subse-
quently, tyrosine-phosphorylated ITAMs serve as docking
sites for Src homology (SH)2 domains present in the two
members of another family of tyrosine kinases, ZAP-70
and Syk. Recruitment of ZAP-70/Syk to the TCR com-
plex activates these kinases which, in concert with Lck,
transduce the TCR signal downstream by phosphorylating
several targets. This activation process ultimately leads to
the transcription of genes such as IL-2, a hallmark of T cell
activation.
The essential role of Lck in TCR signaling has been un-
derscored by the demonstration that a Jurkat T cell line
lacking expression of this kinase is unresponsive to TCR
stimulation (2). Moreover, mice deficient in or expressing a
dominant negative form of Lck display a profound block-
ade in thymocyte development in the transition to the
CD4/CD8 double-positive stage (3, 4). ITAM phosphory-
lation is abrogated in both the Lck-deficient Jurkat line and
Lck-deficient thymocytes (5, 6).
Lck, like other Src family members, has a distinctive struc-
ture. It has a unique NH
 
2
 
-terminal region, followed by SH3,
SH2, catalytic (SH1), and COOH-terminal regulatory do-
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Abbreviations used in this paper:
 
 AP-1, activator protein 1; CI-M6PR,
cation-independent mannose 6-phosphate receptor; FLAG, fluoresce-
inated antigen; GST, glutathione 
 
S
 
-transferase; HRP, horseradish peroxi-
dase; IP, immunoprecipitation; ITAM, immunoreceptor tyrosine-based
activation motif; LAT, linker for activation of T cells; NFAT, nuclear fac-
tor of activated T cells; PDGFR, platelet-derived growth factor receptor;
PTyr, phosphotyrosine; SH, Src homology; SLAP, Src-like adaptor pro-
tein; SLP-76, SH2 domain–containing leukocyte protein of 76 kD; TAg,
large T antigen; WCL, whole cell lysate; WT, wild-type.
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mains. Two functions have been attributed to the unique re-
gion of Lck: (a) myristoylation and palmitoylation of this
 
region target Lck to the plasma membrane, and (b) a cysteine-
containing motif enables it to associate with CD4 or CD8
 
coreceptors (7–10). The SH3 and SH2 domains are well-
defined protein–protein interaction modules (11) and, as
such, facilitate binding of Lck to many signaling molecules.
The SH3 domain can recognize proline-rich sequences
 
within c-Cbl, the p85 subunit of phosphatidylinositol
3-kinase, Ras–GTPase-activating protein, hematopoietic
specific protein 1, and CD2 (12–16). The SH2 domain can
interact with tyrosine-phosphorylated ZAP-70 and Syk ki-
nases (17, 18) or with the negative regulatory site of Lck in
an intramolecular interaction (19). Following the SH2 do-
main is the catalytic domain of Lck. Activation of the kinase
is dependent on autophosphorylation of a single tyrosine
residue within the activation loop of the kinase domain.
Dephosphorylation of a well-conserved tyrosine present in
the COOH-terminal regulatory region is also required for
kinase activation (for a review, see reference 20).
A molecule structurally resembling Src family protein ty-
rosine kinases was cloned using a yeast two-hybrid screen
(21). Like Lck, this Src-like adaptor protein (SLAP) con-
 
tains a short unique NH
 
2
 
-terminal domain, followed by
SH3 and SH2 domains. However, it does not contain a ty-
rosine kinase domain. Both the SH3 and SH2 domains of
SLAP are highly homologous to those of Lck and share
with them 55 and 50% identity, compared with 42 and
43% with c-Src, respectively (K best nonintersecting align-
ments; ExPASy, available at http://www.expasy.ch). The
SLAP SH3 and SH2 domains share less homology with
other SH3 domains (those of phospholipase C-
 
g
 
1 and the
p85
 
a
 
 subunit of phosphatidylinositol 3-kinase share only
20 and 24% identity, respectively) and SH2 domains (those
of Shc and Grb2 share only 25 and 27% identity, respec-
tively [21]). Instead of a kinase domain, SLAP contains a
unique COOH terminus of 104 residues. The initial study
where SLAP was identified suggested ubiquitous expres-
sion of SLAP mRNA among tissues tested. In a subsequent
study, microinjected SLAP inhibited a platelet-derived growth
factor receptor (PDGFR)-dependent mitogenic response in
fibroblasts (22). Biochemical analysis revealed that SLAP as-
sociated with activated PDGFRs, and that it could effi-
ciently compete with Src for PDGFR binding.
Since the original report suggested the possibility of its
expression in T cells, we studied the potential role of SLAP
in regulating TCR signaling. Here, we report that SLAP is
expressed in T lineage cells, and that it can inhibit TCR
signaling when expressed in the Jurkat T cell line.
 
Materials and Methods
 
Cell Lines and Reagents. 
 
Jurkat cells or Jurkat cells transfected
 
with the simian virus 40 large T antigen (SV40 TAg; provided by
G. Crabtree, Stanford University, Stanford, CA) and murine cell
lines were maintained in RPMI 1640 medium supplemented
with 10% FCS, penicillin, streptomycin, and glutamine. HeLa cells
 
were passaged in DME supplemented with 5% FCS. The Ab used
 
for TCR stimulation of Jurkat TAg cells was C305, an anti-Ti 
 
b
 
chain mouse mAb (23). Blotting Abs were as follows: an anti-fluo-
resceinated antigen (FLAG) M2 mAb (Sigma Chemical Co.); an
antiphosphotyrosine (PTyr) mAb, 4G10 (Upstate Biotechnology);
 
an anti-CD3
 
z
 
 mAb, 6B10.2 (24); rabbit anti-linker for activation of
T cells (LAT) serum (25); sheep anti–SLP-76 serum (26); anti–
ZAP-70 mAb, 2F3.2 (5); rabbit anti-Vav serum (Santa Cruz Bio-
technology); rabbit anti–
 
a
 
-tubulin serum (Sigma Chemical Co.);
and anti-Lck mAb, 1F6 (provided by Dr. J. Bolen, Bristol-Meyers
Squibb, Wallingford, CT). Rabbit serum (C1661) directed against
 
the NH
 
2
 
-terminal amino acids (6–25) of murine SLAP was gener-
ated in our laboratory. Two secondary reagents were used: a horse-
radish peroxidase (HRP)-conjugated goat anti–mouse IgG (South-
ern Biotechnology Associates), and HRP-conjugated protein A
(Amersham). For immunofluorescence studies, we used rabbit anti–
murine SLAP C1661 polyclonal Ab or the M2 anti-FLAG mAb to
detect FLAG-tagged murine SLAP, or rabbit anti–cation-indepen-
dent mannose 6-phosphate receptor (CI-M6PR) polyclonal antise-
rum (gift of F. Brodsky, University of California at San Francisco,
San Francisco, CA) to detect CI-M6PR. FITC-conjugated goat
anti–rabbit IgG (GIBCO BRL) or Texas red–conjugated goat anti–
mouse IgG (Caltag) was used as secondary Ab.
 
DNA Constructs. 
 
All expression constructs used to express
SLAP protein contained murine SLAP cDNA fused to the FLAG
epitope tag at its COOH terminus. SLAP cDNA–FLAG inserts
were flanked by BamHI-XhoI sites, and were subcloned into
BamHI-SalI sites of pEF-BOS X-C, a mammalian expression
vector (27). The pEF-SLAP SH3
 
*
 
 had a CCA to CTC mutation,
changing a
 
 
 
P
 
 
 
to L at position 73; the pEF-SLAP SH2
 
*
 
 had a
CGA to GAA mutation, changing an R to E at position 144;
pEF-SLAP 
 
D
 
C expressed a truncated version of SLAP, including
the NH
 
2
 
 terminus, the SH3 and SH2 domains, and 10 amino ac-
ids of the unique COOH terminus (i.e., 1–187). Glutathione
 
S
 
-transferase (GST)-SLAP, GST-Lck(SH2), and pEF-TacT were
constructed as described (18, 21, 28). The nuclear factor of acti-
vated T cells (NFAT) luciferase and IL-2 luciferase reporters were
provided by G. Crabtree. Activator protein 1 (AP-1) luciferase was
described previously (29). pRc/
 
b
 
gal was a gift from M. Karin
(University of California, San Diego, CA).
 
Northern Blot Analysis. 
 
Tissues were derived from C57BL/6
 
mice. Total RNA was extracted using RNAzol (Tel-Test). 10 
 
m
 
g of
total RNA per sample was stained with ethidium bromide, resolved
on agarose gel, and transferred onto MagnaCharge Nylon mem-
 
brane (Micron Separations, Inc.). The blot was hybridized with a
 
[
 
32
 
P]dCTP-labeled XcmI-ScaI fragment encompassing 330 nucleo-
tides) encoding the unique COOH terminus of murine SLAP.
 
Transfections and Luciferase Assays. 
 
2 
 
3
 
 10
 
7
 
 Jurkat TAg cells
were resuspended in 400 
 
m
 
l of serum-free RPMI medium con-
taining plasmid DNA, placed in a 0.4-cm cuvette, and electropo-
rated at 250 V, 960 
 
m
 
F using the Bio-Rad Gene Pulser elec-
troporator. Cells were harvested after 16–24 h, and were stimulated
 
with soluble anti-TCR Ab C305 (1:1,000 dilution of ascites), PHA
 
(1 
 
m
 
g/ml), PMA (50 ng/ml), or ionomycin (1 
 
m
 
M), or with the
indicated combination of reagents. After 8 h, cells were lysed and
assayed for luciferase activity as described (30). All transfections
included the pRc/
 
b
 
gal plasmid (31) to normalize for differences
in gene transfer by assay of 
 
b
 
-galactosidase activity, which was
performed using a chemiluminescence assay system (Tropix).
 
Cell Enrichment and Immunoprecipitations. 
 
Jurkat TAg cells were
transiently cotransfected with pEF-TacT and the indicated effec-
tor plasmids. After 12 h, cells were harvested, washed in PBS, and
resuspended in MACS
 
®
 
 purification buffer (PBS, 0.5% BSA, 2 mM
EDTA; Miltenyi Biotec). Cells were then stained with FITC-
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conjugated anti-Tac mAb (anti-CD25 FITC; Becton Dickinson)
followed by anti-FITC MultiSort MicroBeads (Miltenyi Biotec),
 
and were purified on a VS
 
1
 
 column according to the manufac-
turer’s protocol. The purity of isolated cells was determined using
flow cytometry (FACScan™; Becton Dickinson). Tac
 
1
 
 enriched
populations were lysed in lysis buffer containing 1% NP-40, 10
mM Tris (pH 7.8), 150 mM NaCl, 2 mM EDTA, and protease
and phosphatase inhibitors. Lysates were normalized for protein
concentration using the Bradford assay (Bio-Rad). After addition
of SDS to a final concentration of 1%, lysates were incubated on
ice for 10 min, boiled for 5 min, diluted to final 0.5% SDS with 1%
NP-40 lysis buffer, briefly sonicated to shear the genomic DNA,
and centrifuged at 100,000 
 
g
 
 for 30 min. Soluble lysates were incu-
 
bated with 1 
 
m
 
g of rabbit anti–murine SLAP C1661 polyclonal Ab
cross-linked to protein A–Sepharose beads (Amersham Pharmacia
Biotech) for 2 h. Beads were washed four times with 1% NP-40
buffer, and were boiled for 5 min in SDS sample buffer. A standard
protocol for Western blotting was followed: proteins were sepa-
rated by SDS-PAGE, transferred to Immobilon-P (Millipore)
membrane, and immunoblotted with C1661 Ab followed by a
protein A conjugated to HRP (Amersham). Enhanced chemilumi-
nescence was used to detect immunoreactive proteins (Amersham).
 
Measurement of Intracellular Calcium. 
 
Tac
 
1
 
 cells were selected
as described above, and were cultured for 2 h to allow cell recov-
ery from the purification procedure. To assay intracellular cal-
cium concentration, cells were loaded with Indo-1 (Molecular
Probes), washed, and then stimulated with C305 mAb (1:1,000)
followed by ionomycin (1 
 
m
 
M). The fluorescence intensities at
400 and 500 nm wavelengths were measured using a Hitachi
F-4500 spectrofluorometer, and were used to calculate concen-
tration of intracellular calcium (32).
 
Immunofluorescence Microscopy. 
 
Jurkat TAg cells were transiently
transfected as above, incubated for 12–16 h, and seeded onto
 
poly-
 
l
 
-lysine–coated slides. HeLa cells were transiently trans-
fected using the calcium phosphate method, and were incubated
on a chambered coverglass (Lab-Tek) to allow for cell adhesion.
Next, Jurkat TAg or HeLa cells were fixed in 3.4% paraformalde-
hyde at room temperature for 20 min, followed by a 4-min per-
meabilization in 0.1% Triton X-100 in PBS, and 10 min of
blocking in 0.2% BSA in PBS. Cells were incubated with primary
Abs for 30 min, washed twice with 0.2% BSA in PBS, and
stained with secondary Abs. MOWIOL
 
®
 
 (Calbiochem) supple-
mented with 2.5% Dabco™ (Sigma Chemical Co.) was used to
mount the coverslips and prevent photobleaching. Confocal fluo-
rescence microscopy was performed using a Bio-Rad MRC1000
confocal imaging system interfaced to a Zeiss inverted micro-
scope equipped with a 100
 
3
 
 NA 1.3 objective.
 
GST Pulldowns, Immunoprecipitations, and Western Blotting. 
 
Jur-
kat cells were left untreated or were stimulated with C305 mAb
(1:1,000 dilution of ascites) for 2 min, and lysed in 1% NP-40 ly-
sis buffer. Procedures for GST pulldowns and immunoprecipita-
tions (IPs) were described previously (18). For GST pulldown
experiments, 2 
 
m
 
g of each GST fusion protein was incubated
 
with lysates obtained from 5 
 
3
 
 10
 
7
 
 cells for 2 h. For IPs, 1 
 
m
 
g of
rabbit anti-SLAP C1661 affinity-purified Ab or 1 
 
m
 
g of anti-Lck
1F6 mAb was incubated with lysates obtained from 3 
 
3
 
 10
 
7
 
transfected cells. Both Abs were cross-linked to protein A–Seph-
arose beads (Amersham Pharmacia Biotech) before IPs. A stan-
dard protocol for Western blotting was followed (see above).
 
Results
 
Tissue- and Cell Type–specific Expression of SLAP mRNA.
 
As the first step in our analysis of SLAP, we studied its tis-
sue-specific expression in mouse tissues and cell lines. SLAP
mRNA is predominantly expressed in lymphoid tissues,
though low levels can be detected in the lung and brain (Fig.
1 A). To further elucidate the cell types that express SLAP
mRNA, we compared message levels in purified splenic T
cells, purified splenic B cells, and in various cell lines repre-
senting fibroblasts, macrophages, mast cells, B cells, and T
cells (Fig. 1 B). Note that EL-4 thymoma was the only mu-
rine cell line we analyzed that expressed significant levels of
the message. After longer exposure of the Northern blot,
Raw264.7 and P815 cells had detectable levels, but NIH
3T3 cells did not. Strikingly, both primary T cells and pri-
mary B cells expressed significant levels of SLAP mRNA.
Based on these data, we conclude that T lineage cells and B
lineage cells are the predominant cell types expressing SLAP.
 
Effect of SLAP Expression on TCR-induced Transcriptional
Responses. 
 
Having demonstrated endogenous SLAP tran-
scripts in thymocytes and primary T cells, we wanted to
study the functional consequences of the presence of SLAP
protein in T cells. We analyzed the effects of SLAP expres-
sion in Jurkat TAg cells on one measure of TCR signaling,
the transcriptional activity of the IL-2 promoter and its two
elements, NFAT and AP-1. Although Jurkat and Jurkat
TAg cells expressed SLAP mRNA, we have not been able
to detect SLAP protein in these cell lines (data not shown).
We started our analysis by using a very sensitive reporter
of TCR signaling, the luciferase gene under the control of
an NFAT element arranged in triplicate (NFAT luciferase).
Transient expression of SLAP in Jurkat TAg cells potently
inhibited TCR-driven NFAT transcription in a dose-
dependent manner (Fig. 2 A). To determine whether the in-
hibitory effects of SLAP can occur at physiological amounts
of the protein, we compared the levels of SLAP in these
transfected Jurkat TAg cells (cells were from the same ex-
Figure 1. SLAP is predominantly
expressed in the lymphoid tissues.
Northern blot analysis was performed
on (A) multiple tissues, (B) various
cell lines (fibroblast [NIH 3T3],
macrophage [Raw264.7], mastocy-
toma [P815], B cell lines, and T cell
lines), and enriched splenic B and T
cells (.92% and 98% pure, respec-
tively). A 32P-labeled DNA fragment
from the unique COOH terminus of SLAP cDNA was used to detect SLAP mRNA present in 10 mg of total RNA. Equal loading and complete transfer of
RNA were confirmed by ethidium bromide staining and quantitation of ribosomal 28S and 18S RNA using the Bio-Rad Gel Doc 1000 system (bottom panels).
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periment shown in Fig. 2, A and B) with the level present
in a murine thymoma line EL-4. To ensure appropriate
comparison of EL-4 to only those Jurkat TAg cells that were
successfully transfected with SLAP, we also had cotrans-
fected a tag to mark the transfected cells—a plasmid encod-
ing the extracellular and transmembrane domains of Tac
(IL-2R 
 
a
 
 chain). By enriching for Tac-expressing cells us-
ing magnetic beads, we separated SLAP-expressing cells
from the nontransfected cells (populations were 
 
.
 
97%
 
Tac
 
1
 
; e.g., the purification profile for cells transfected with
0.25 
 
m
 
g of SLAP is shown in Fig. 2 D). We used this puri-
fication approach since we and others have established that
Jurkat cells proportionately coexpress cotransfected plas-
mids (30, 33). By immunoprecipitating SLAP from equiva-
lent amounts of cell lysates, we could appropriately com-
pare the level of SLAP in the transfected population to the
level present in EL-4. We established that 0.25–0.5 
 
m
 
g of
transfected pEF-SLAP plasmid resulted in levels of SLAP
protein comparable with that present in EL-4 cells (Fig. 2
C). Significantly, even the transfection of 0.25 
 
m
 
g of pEF-
SLAP plasmid significantly inhibited the NFAT reporter.
These results indicate that SLAP can negatively regulate
TCR signaling when expressed at approximately physiolog-
ical (EL-4 cells) levels (Fig. 2, A and C).
This suppressive effect was not limited to the NFAT ele-
ment, since SLAP could also inhibit TCR-dependent acti-
vation of AP-1 and IL-2 luciferase reporters (Fig. 3, A and
C). To stimulate the IL-2 luciferase reporter, we used a
combination of PHA and PMA, an effective stimulus
known to induce transcriptional activity of the IL-2 pro-
moter in a TCR-dependent manner (34). SLAP did not in-
terfere with the general transcriptional machinery in a non-
specific manner, since it had no effect on NFAT, AP-1, or
the IL-2 promoter in cells stimulated with PMA and the
calcium ionophore (ionomycin; Fig. 2 B and Fig. 3, B and
D), nor did it suppress the luciferase activity under the con-
trol of the constitutive Rous sarcoma virus (RSV) pro-
moter (data not shown). The ability of PMA and ionomy-
cin—pharmacological agents that bypass proximal TCR
signaling by activating Ras and increasing intracellular cal-
cium, respectively—to activate transcription in the presence
of SLAP places the SLAP-imposed blockade more proxi-
mal in the TCR signaling pathway than Ras activation and
calcium increases. Moreover, TCR-dependent activation
Figure 2. SLAP inhibits TCR induction of NFAT-driven transcription
in a dose-dependent manner. Jurkat TAg cells were cotransfected with
four different plasmids: a luciferase reporter under the transcriptional con-
trol of a multimerized NFAT element (NFAT luciferase); a transfection
efficiency indicator (pRc/bgal); a transfection tag (pEF-TacT); and an ef-
fector plasmid (either pEF-SLAP or an empty vector, pEF-BOS). The to-
tal amount of DNA was kept constant by supplementing the various
amounts of pEF-SLAP plasmid with an empty vector. After 16–24 h, cells
from each transfection were tested for the transfection efficiency by
b-galactosidase assay (data not shown), or incubated for an additional 8 h
with medium alone (Media), soluble anti-TCR mAb (C305), or PMA
and ionomycin (PMA1Ion), and were assayed for luciferase activity. Lu-
ciferase activity was normalized to b-galactosidase and is presented in rel-
ative light units (RLU; A and B). Cells were also tested for the level of
SLAP protein: transfections containing 0.25, 0.5, or 1.0 mg of pEF-SLAP
were enriched for Tac1 cells by magnetic beads (D) and used for IPs of
the ectopically expressed SLAP (C; see Materials and Methods). As posi-
tive and negative controls for the presence of murine SLAP, EL-4 and
nontransfected Jurkat TAg cells were used, respectively.
Figure 3. SLAP inhibits TCR induction of both AP-1– and IL-2 pro-
moter–driven transcription in a dose-dependent manner. Cells were
cotransfected with three different plasmids: a luciferase reporter under the
transcriptional control of either AP-1 element (A and B) or IL-2 pro-
moter (C and D); a transfection efficiency indicator (pRc/bgal); and an
effector plasmid (either pEF-SLAP or an empty vector, pEF-BOS). After
16–24 h, transfected cells were assayed for b-galactosidase activity, and
stimulated with either C305 (A), PMA (B), PHA and PMA (C), or a
combination of PMA and ionomycin (PMA1Ion, D), as indicated (see
Materials and Methods). The activity of each reporter is presented as de-
scribed in the legend to Fig. 2.
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of both the Ras and Ca
 
2
 
1
 
 pathways is inhibited by SLAP,
since stimulation of cells with anti-TCR Ab and either
PMA alone or ionomycin alone did not bypass the block-
ade (data not shown).
 
Functional Effect of SLAP Expression on TCR-induced Ca
 
2
 
1
 
Flux and Protein Tyrosine Phosphorylation. 
 
Since PMA and
ionomycin treatment bypassed SLAP-dependent inhibition
of NFAT induction, but anti-TCR plus PMA stimulation
did not, we reasoned that SLAP might suppress the TCR-
dependent Ca
 
2
 
1
 
 flux. To examine this, we cotransfected
SLAP or an empty vector with a plasmid encoding Tac, and
enriched for Tac-expressing cells as described above (popu-
lations were 
 
.
 
98% Tac
 
1
 
; Fig. 4 A). As shown in Fig. 4 B,
cells transfected with SLAP, when compared with the vec-
tor-transfected cells, showed a substantially reduced cal-
cium flux in response to anti-TCR stimulation. Importantly,
this pattern of responsiveness was reversed upon subsequent
stimulation of cells with ionomycin. Note that SLAP-trans-
fected cells responded to the calcium ionophore by mobi-
lizing more intracellular Ca
 
2
 
1 than vector-transfected cells.
As a control in this same experiment, we also transfected
the NFAT luciferase reporter plasmid to show that SLAP
was expressed at levels sufficient to inhibit the TCR signal-
ing pathway leading to NFAT activation (Fig. 4 C). We
employed the same approach of cotransfection and enrich-
ment for Tac1 cells to study the effect of SLAP on TCR-
dependent increase in protein tyrosine phosphorylation.
However, we failed to observe any differences in the pat-
tern of tyrosine phosphorylation in total cell lysates from
TCR-stimulated cells when SLAP was expressed (data not
shown).
Contribution of the SH2, SH3, and the Unique COOH-termi-
nal Domains to the Inhibitory Function of SLAP. To study the
mechanism by which SLAP inhibits TCR signaling, we
studied the role of the SH2, SH3, and the unique COOH
terminus of SLAP. As shown in Fig. 5, inactivation of the
SLAP SH2 domain by replacing an arginine with a glutamic
acid in the “FXXR” motif in the phosphotyrosine binding
pocket had a profound effect on the SLAP inhibitory activ-
ity. The SLAP SH2 mutant displayed only a weak inhibi-
Figure 4. SLAP inhibits TCR-dependent Ca21 mobilization in Jurkat cells. Jurkat TAg cells were transiently cotransfected with three plasmids: NFAT
luciferase, pEF-TacT, and pEF-SLAP or an empty vector. 16 h later, transfected cells were enriched based on expression of Tac on the cell surface (see
Materials and Methods). Highly enriched populations (A) were loaded with the fluorescent dye indicator Indo-1, then stimulated with soluble anti-TCR
mAb (C305) followed by ionomycin (arrows indicate the time of stimulation), and the change in intracellular Ca21 concentration was measured as a
function of time (B). Cells from the same experiment were also tested for TCR-dependent NFAT induction (C).
Figure 5. Both SH2 and SH3 domains of SLAP participate in inhibition
of anti-TCR–induced NFAT activity. Jurkat TAg cells were cotransfected
with an NFAT luciferase reporter and various amounts of one of the fol-
lowing effector plasmids: a WT SLAP (WT), an SH2 domain point mutant
(SH2*), an SH3 domain point mutant (SH3*), an SH2 and SH3 domain
double point mutant (SH2*SH3*), and a mutant with deleted COOH ter-
minus (DC). An empty vector was used as a control, and the total amount
of DNA was kept constant by adding empty vector DNA. Individual trans-
fections were matched based on the expression level of the various SLAP
proteins (bottom). TCR-dependent increase in NFAT activity was calcu-
lated as a fold induction, and represents a ratio of luciferase counts of anti-
TCR over media-treated cells. Fold induction obtained for vector-trans-
fected cells was defined as maximum (100% MAX).
468 SLAP Is a Negative Regulator of TCR Signaling
tory effect, despite being expressed at higher levels than the
wild-type (WT) protein. Inactivation of the SH3 domain
by replacing a conserved proline with leucine at position
73 (35) had a more modest effect on SLAP inhibitory func-
tion. However, when both the SH2 and the SH3 domains
were mutated in the same construct, no inhibition of TCR
signaling was observed, suggesting that both domains con-
tribute to the SLAP inhibitory function in an additive man-
ner. In contrast, the unique COOH terminus of SLAP did
not play any role in the inhibition, since a mutant lacking
this domain (SLAP DC) suppressed NFAT induction to the
same extent as the WT protein.
Subcellular Distribution of SLAP. We extended the struc-
ture–function analysis of SLAP to include subcellular local-
ization of the WT protein and the various mutants. Indirect
immunofluorescence staining showed perinuclear localiza-
tion of SLAP in transiently transfected Jurkat TAg cells
(Fig. 6 B). This staining was similar to that of an intracellu-
lar pool of Lck in Jurkat cells, which was reported to colo-
calize with the endosomal marker CI-M6PR (36). How-
ever, because Jurkat cells are small and have large nuclei
and a thin rim of cytoplasm, thereby preventing good reso-
lution of cellular structures, we used HeLa cells to aid in a
more precise SLAP cellular localization. Using indirect im-
munofluorescence to identify CI-M6PR (Fig. 6 D, green)
and SLAP (Fig. 6 E, red), then overlaying the images, the
appearance of yellow confirms that the two molecules
colocalize (Fig. 6 F). Note that of two cells present in the
field (Fig. 6 D), only one was transfected and expressed
SLAP (Fig. 6 E). The same pattern of staining was obtained
with two different primary Abs recognizing distinct epitopes
on transfected SLAP (data not shown; see Materials and
Methods). The observed SLAP staining was specific, since
vector transfected cells did not stain with either Ab (data
not shown).
Next, we asked which of the domains of SLAP played a
role in its colocalization with endosomes by transfecting
various mutants into Jurkat TAg or HeLa cells and staining
for SLAP and CI-M6PR. Mutants with the inactivated
SH2 domain (SH2* and SH2*SH3*) were the only ones
that did not correctly colocalize with endosomes. Instead,
they displayed diffuse vesicular staining (Fig. 6, G–I, and
data not shown). This difference in staining indicates that
the endosomal localization of WT SLAP was not an artifact
of overexpression, since both WT and SH2 mutants were
expressed at similar levels. The same pattern of staining was
obtained for Jurkat cells (data not shown). Collectively,
these data suggest that the SH2 domain of SLAP targets it
to the cytoplasmic face of endosomes, most likely by ty-
rosine phosphoprotein(s).
Insolubility of SLAP in Mild Detergents. During the course
of our studies, we discovered that SLAP protein is insoluble
in mild detergents (Fig. 7). The insolubility of SLAP does
not depend on the actin cytoskeleton or on interactions
Figure 6. The SLAP SH2 do-
main is required for its colocaliza-
tion with endosomes. Jurkat (A,
B, and C) and HeLa cells (D–I)
were transiently transfected with
pEF-SLAP WT plasmid (A–F) or
with pEF-SLAP SH2* mutant
(G–I), and the indirect immuno-
fluorescence analysis was per-
formed (see Materials and Meth-
ods). The endogenous endosomal
marker, CI-M6PR, is present in
all cells (green); however, SLAP is
present only in transiently trans-
fected cells (red). To depict the
degree of colocalization of SLAP
and CI-M6PR, the red and green
channels were merged (C, F, and
I, OVERLAY). Each image rep-
resents a single section through a
field of cells.
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with microtubules, since its insolubility was not sensitive to
cytochalasin D or nocodazole (data not shown). This prop-
erty is dependent on the unique COOH-terminal domain,
since the mutant lacking this domain partitioned to the 1%
NP-40 soluble fraction. The equal distribution of SLAP
DC into soluble and pellet fractions in Fig. 7 (experiment
1) was due to high levels of expression, since the same mu-
tant was present predominantly in the soluble fraction
when expressed at lower levels in experiment 2. SLAP in-
solubility does not correlate with its inhibitory function be-
cause, as shown in Fig. 4, SLAP DC was as potent in inhib-
iting NFAT induction as the WT SLAP.
A Specific Subset of Phosphoproteins Interacts with SLAP.
Given the critical importance of the SH2 domain for SLAP
function, we wished to identify the tyrosine-phosphory-
lated proteins that interact with SLAP. Since WT SLAP is
insoluble in the mild detergents that are used for solubiliza-
tion and are necessary to preserve protein–protein interac-
tions, we were unable to perform direct IPs of WT SLAP
protein. Instead, we used two different approaches to iden-
tify the phosphoproteins that interact with SLAP. First, we
used a GST pulldown experiment to detect in vitro inter-
actions. Among many inducibly tyrosine-phosphorylated
proteins present in Jurkat lysates, 24-kD phosphoproteins
(pp24), pp36/38, pp76, and pp95 were consistently bound
by GST-SLAP (Fig. 8, see arrowheads and bracket). Other
bands present in Fig. 8, notably the bands corresponding to
putative pp34, pp46, and pp60, were not consistently seen.
GST did not retain any substantial amounts of phosphopro-
teins by itself, indicating the specificity of the interactions.
Notice that an almost identical set of proteins was retained
by the GST-Lck SH2 domain, but not by the GST-Grb2
construct. These results suggest that a subset of TCR-induced
tyrosine phosphoproteins interact specifically with SLAP in
vitro.
Our second approach was aimed at identification of in
vivo interactions, and took advantage of the solubility of
the SLAP DC mutant. We reasoned that this mutant should
bind to the same target phosphoproteins as WT SLAP,
since both proteins similarly inhibited TCR-induced NFAT
activation, and they both localized to the same cellular
structures. We compared anti-SLAP IPs from cells trans-
fected with SLAP DC with anti-Lck IPs from cells trans-
fected with an empty vector (Fig. 9). Lack of phosphopro-
teins in anti-SLAP IPs from cells transfected with vector
alone indicates the specificity of the interactions. In addi-
tion to the phosphoproteins already identified by GST pull-
down experiments (pp24, pp36/38, pp76, and pp95; Fig.
8), we consistently observed three new species in both
SLAP and Lck IPs: pp50, pp56, and pp70 (Fig. 9, see ar-
rowheads and bracket). To identify the proteins detected
by anti-PTyr blotting, we reprobed the blot with Abs spe-
cific for the proteins known to participate in TCR signal-
ing and having similar mobility on SDS-PAGE. pp24 was
confirmed to contain CD3 z chain, pp50 contained a-tubu-
lin, pp56 contained Lck, pp70 contained ZAP-70, pp76
contained SLP-76, and pp95 contained Vav. pp36/38 is
likely to represent LAT, but we could not confirm this by
Western blotting with anti-LAT heteroserum, perhaps be-
cause of the difficulty in detecting phospho-LAT with this
Figure 7. The unique COOH terminus
of SLAP determines its insolubility in mild
detergents. Jurkat cells were transiently
transfected with an expression plasmid en-
coding either WT SLAP or the indicated
mutants. After 24 h, cells were lysed in 1%
NP-40 lysis buffer, and the detergent-solu-
ble (S) and the pellet (P) fractions were sep-
arated by standard centrifugation procedure
(see Materials and Methods). Pellet fractions
were solubilized in the SDS-PAGE loading
buffer, and cell-equivalent amounts were
run on SDS-PAGE. SLAP protein was de-
tected by Western blotting using rabbit
anti-SLAP C1661 Ab. EXP, experiment;
MWM, molecular weight marker.
Figure 8. SLAP interacts in vitro with a specific subset of phosphopro-
teins. Lysates from unstimulated (2) or stimulated (1) Jurkat TAg cells
were used in the GST pulldown experiment with the indicated fusion
proteins (see Materials and Methods). Tyrosine-phosphorylated proteins
that interacted with the fusion proteins were resolved by SDS-PAGE and
detected with the anti-PTyr mAb (4G10). Soluble WCLs were used as a
control for stimulation. Molecular weight markers are indicated on the
left (MWM), and the phosphoproteins consistently present in GST-SLAP
pulldowns are marked by arrowheads and a bracket on the right.
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reagent. Although pp36/38 and pp50 were predominantly
present in SLAP DC IPs, we could also detect pp36/38 in
Lck IPs on longer exposure of the blot. These results dem-
onstrate that SLAP interacts, both in vitro and in vivo, with
many proteins known to participate in TCR signaling.
Discussion
In this study, we found that SLAP can function as a neg-
ative regulator of TCR signaling. The T cell is a relevant
cell type for studying SLAP function, since SLAP is ex-
pressed in T and B lineage cells. Overexpression of SLAP
in Jurkat T cells potently inhibited the TCR-dependent
increase in NFAT-driven transcription. Inhibition of AP-1
and IL-2 transcription was also observed. A structure–func-
tion analysis revealed that both the SH3 and SH2 domains
contribute to this inhibitory function. WT SLAP protein
colocalized with the CI-M6PR associated with endosomes,
but SLAP mutants with inactive SH2 domain exhibited an
altered diffuse, vesicular pattern. SLAP was insoluble in
mild detergents, and this property depended on the unique
COOH terminus. In stimulated Jurkat cells, SLAP associ-
ated with many proteins from the TCR signaling complex.
Collectively, these results suggest that SLAP interacts with
the stimulated TCR complex to downregulate TCR-medi-
ated signals.
It was originally thought that SLAP RNA is expressed
ubiquitously among various tissues (21), and endogenous
protein was detected in NIH 3T3 fibroblasts (22). Here, we
extended the study of SLAP expression to immune tissues
and several cell lines representing different cell types. We
confirm the finding of Pandey et al. (21) that the spleen ex-
presses high levels of SLAP mRNA, but we find that high
level of expression is restricted to the immune tissues, with
the highest level present in the thymus. In addition, among
various cell types tested, only thymocytes, the purified pri-
mary T cells and B cells, and a T cell line (EL-4) expressed
high levels of SLAP message. Our studies used Northern
blots containing 10 mg of total RNA (Fig. 1) instead of 2 mg
of enriched poly-A messenger RNA (21). Therefore, we
could detect only relatively high levels of expression in
lymphoid tissues. Unlike the data of Roche et al. (22), who
used a heterologous rabbit serum and reported that NIH
3T3 fibroblasts expressed endogenous SLAP protein, we
were unable to detect SLAP RNA in NIH 3T3 cells. This
difference might be due to clonal variability. However, we
would suggest that the high level of SLAP expression is
specific to the immune tissues, and that T cells and B cells
are predominant cell types expressing it.
Structural resemblance of SLAP to Src family kinases and
the recent finding that microinjected SLAP can negatively
regulate a Src-dependent receptor signaling pathway of the
PDGFR in fibroblasts (22) suggested that SLAP could be a
common negative regulator of signaling pathways depen-
dent on activity of Src family members. Since TCR signal-
ing requires Src family (Lck or Fyn) kinase activity (2, 37), we
tested the effects of SLAP overexpression in Jurkat cells on
TCR signaling. Consistent with the role of SLAP in PDGFR
signaling, we find that SLAP overexpression in Jurkat T
cells significantly inhibited TCR-induced signal transduc-
tion as measured by transcriptional activity of IL-2 pro-
moter and two of its integral elements, NFAT and AP-1.
SLAP did not inhibit general transcription in a nonspecific
manner, since a constitutively active promoter of Rous sar-
coma virus was not affected. These results suggest that the
presence of adequate levels of SLAP protein in T cells could
render them unresponsive to TCR signaling. Consistent
with this hypothesis, we found that Jurkat cells, which re-
spond to TCR stimulation very well, do not express detect-
able endogenous SLAP protein. However, EL-4 cells, which
respond to anti-TCR engagement very poorly, express SLAP
at a level sufficient to significantly inhibit NFAT induction
when ectopically expressed in Jurkat. Preliminary studies
suggest that the level of SLAP protein in T cells may be
regulated after transcription. We found that thymocytes,
despite expressing high levels of RNA, express very low
levels of SLAP protein (data not shown). Moreover, resting
T cells, a majority of which can be activated by engagement
of their TCRs, express SLAP RNA but no detectable
SLAP protein (as determined by IPs followed by Western
blotting; data not shown). Stimulation of both populations
of cells has little effect on RNA levels, but protein levels
are induced. Further studies will be required to understand
the exact mechanism responsible for the regulation of
SLAP protein levels.
The inhibitory effects of SLAP appear to influence prox-
imal events involved in TCR signaling, since ionomycin-
and PMA-mediated stimulation of IL-2–, AP-1–, and
Figure 9. SLAP interacts in vivo with a specific subset of phosphopro-
teins. Jurkat TAg cells were transiently transfected with either an empty
vector or pEF-SLAP DC. After 12–16 h, cells were either left unstimu-
lated (2) or stimulated with soluble anti-TCR Ab (C305) for 2 min (1),
and lysed in 1% NP-40 lysis buffer. Equivalent amounts of lysates were
used in anti-Lck and anti-SLAP IPs (see Materials and Methods). Subse-
quently, WCLs or washed immunoprecipitates were separated by SDS-
PAGE and probed with anti-PTyr mAb (4G10). MWM, molecular
weight marker.
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NFAT-directed transcription was insensitive to SLAP inhi-
bition. The ability of SLAP to uncouple TCR signaling from
transcriptional activation of NFAT may, in part, be due to
reduced levels of TCR-induced calcium fluxes. Though
incomplete, an attenuated TCR-induced Ca21 flux was ob-
served in the presence of SLAP. Notably, anti-TCR stimu-
lation in conjunction with PMA, which should bypass the
SLAP-imposed blockade of the protein kinase C/Ras path-
way, could not restore NFAT-driven transcription (data not
shown). This result indicates that TCR signaling did not
generate a sufficient calcium signal in the presence of SLAP
to synergize with PMA. Interestingly, J14 cells, a Jurkat
mutant deficient in SLP-76 expression, displayed a similar
partial reduction in TCR stimulation–induced Ca21 flux,
and were also unable to upregulate NFAT-driven transcrip-
tion when stimulated with anti-TCR Ab and PMA (38). Sim-
ilar epistasis studies using anti-TCR plus ionomycin suggest
that SLAP blocks the function of the protein kinase C/Ras
pathway (data not shown). However, we have failed to de-
tect any influence of SLAP on the pattern of TCR-induced
protein tyrosine phosphorylation (data not shown). This is
not a completely surprising finding, since analysis of protein
tyrosine phosphorylation in the whole cell lysates (WCLs)
is a very crude way to assess the integrity of the TCR sig-
naling pathway. For example, the only difference observed
in SLP-76–deficient J14 cells was the lack of tyrosine phos-
phorylation of the band corresponding to SLP-76 itself, de-
spite the fact that phospholipase C-g1 phosphorylation was
also impaired (38). Additional studies will be required to
determine whether SLAP prevents tyrosine phosphoryla-
tion of specific substrates or serves to relocalize them (for
example, by targeting them to endosomes).
Our structure–function analysis showed additive contri-
butions of both the SH3 and SH2 domains of SLAP to its
inhibitory function, with the SH2 domain having a stron-
ger effect. Even though no functional effect of the COOH
terminus of SLAP on TCR signaling was observed, we
speculate that this unique 104–amino acid region might
play a role in regulating the protein stability since it contains
potential proline-, glutamic acid–, serine-, and threonine-
rich (PEST) sequences (39), thereby influencing the level
of SLAP protein available to regulate the TCR response.
Curiously, this unique COOH-terminal part renders SLAP
insoluble in mild detergents.
SLAP protein accumulated in perinuclear structures in
Jurkat cells. Indirect immunofluorescence analysis of ectopi-
cally expressed SLAP in HeLa cells enabled a better resolu-
tion of cellular structures and confirmed colocalization of
SLAP with an endosomal marker, CI-M6PR. Interestingly,
similar localization was reported for an intracellular pool of
Lck (35). Because our functional data place SLAP-dependent
blockade upstream of effects caused by PMA and ionomycin,
we were surprised that, unlike Lck, no plasma membrane
staining was observed for SLAP. However, recruitment of
SLAP to the plasma membrane might require TCR stimula-
tion, and it would be difficult to detect this in transfected
Jurkat cells where only a thin rim of cytoplasm is seen in
immunofluorescent microscopic studies. Moreover, the in-
direct immunofluorescence analysis might not be sensitive
enough to detect low, yet functionally significant, amounts
of SLAP in the plasma membrane. A similar observation was
reported for CTL-associated antigen 4 (CTLA-4) protein
where only the intracellular, but not the plasma membrane
localization was detected by immunofluorescence staining
(40). Therefore, like CTL-associated antigen 4, SLAP pro-
tein may rapidly shuttle from the plasma membrane to endo-
somes. Such shuttling to the plasma membrane may depend
on TCR signaling. Since the inhibitory effects of SLAP and
its localization depended on its SH2 domain, SLAP could
play a role in downregulating the stimulated TCR complex.
Having established that SLAP interferes with the proxi-
mal events of TCR signaling, and knowing that it structur-
ally resembles Lck, we hypothesized that both proteins
could interact with a similar set of targets. Indeed, the pat-
tern of phosphoproteins interacting in vitro and in vivo
with both proteins is very similar. Notably, tyrosine-phos-
phorylated TCR z chain, ZAP-70, SLP-76, and Vav, as
well as a 36/38-kD protein which likely represents LAT, were
all present in the SLAP-interacting complexes. We were un-
able to confirm these results with an endogenously ex-
pressed SLAP in EL-4 cells, since SLAP protein is insoluble
in mild detergents necessary to preserve protein–protein in-
teractions. These data showed that SLAP and Lck can in-
teract with TCR-containing signaling complexes of similar
composition.
Since the original submission of this manuscript, another
study examining the role of SLAP in T cells was reported by
Tang et al. (41). Although both studies used the transient
transfection system in Jurkat cells, Tang et al. found that ex-
pression of a GST-SLAP fusion protein potentiated TCR-
induced NFAT responses, in marked contrast to the inhibi-
tory effects we observed. The apparent difference could relate
to the use of a GST fusion of SLAP by Tang et al., rather than
epitope-tagged proteins used by us. We confirmed our results
by using a different construct encoding a myc-tagged human
SLAP (data not shown). Moreover, Tang et al. used only a
single dose of GST-SLAP plasmid, whereas we used a broad
range of SLAP-encoded plasmid and found a dose-dependent
inhibitory effect on IL-2, NFAT, and AP-1 reporters. None-
theless, despite the differences, our results are in agreement
with the findings of Tang et al. that SLAP interacts with a set
of proteins relevant to TCR signal transduction.
In conclusion, the data presented here demonstrate that
SLAP can function as a negative regulator of TCR func-
tion by interfering with the proximal signaling events.
Therefore, the differential expression of SLAP protein in T
cells could potentially regulate sensitivity to TCR stimula-
tion, thus influencing thymocyte development and mature
T cell responses to antigenic stimulation. We are currently
testing this hypothesis using SLAP-deficient mice.
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